Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

raltegravir

- PMLiVE

Merck files once-weekly DPP-4 inhibitor in first market

Picks Japan to submit omarigliptin

- PMLiVE

Merck buys rights to NewLink’s Ebola vaccine

Drug is set to enter large phase III study in early 2015

- PMLiVE

Merck & Co’s cancer drug Keytruda gaining traction in US

Anti-PD-1 drug is used in around three quarters of eligible patients in US just weeks after FDA approval

- PMLiVE

GSK to sell off part of its HIV venture ViiV Healthcare

And sets out new restructure programme as US Seretide sales hit

- PMLiVE

Russian HIV vaccine heading for phase II trials

But trials could be affected by lack of funding

- PMLiVE

Nimbus looks to Merck for CEO

Donald Nicholson spent 26 years at US pharma giant

Bristol-Myers Squibb (BMS) building

BMS takes PD-1 rivalry with Merck to the law courts

Claims Keytruda infringes antibody patents it holds with Ono Pharmaceutical

- PMLiVE

Merck brings first PD-1 inhibitor to US market

FDA approves Keytruda for advanced melanoma

- PMLiVE

H4B’s charity team launches Catalyst4Change

The comms agency aims to 'help smaller charities be heard'

- PMLiVE

Pfizer and Merck expand anti-PD1 cancer alliance

Will investigate combination of pembrolizumab and Xalkori

- PMLiVE

Merck enlists celebrity chef in Hispanic diabetes campaign

Leticia Moreinos Schwartz will help get healthy eating message to Latin Americans

- PMLiVE

Merck and Advaxis to study anti-PD1 combo

Collaboration to investigate pembrolizumab and ADXS-PSA in prostate cancer

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links